Effects of ultrasound-guided erector spinae plane block with dexmedetomidine combined with ropivacaine of the same dose and different concentrations on analgesic effect and rehabilitation quality of patients undergoing thoracoscopic wedge resection of the lung: a prospective, randomized, controlled trial

Chunfang Jian, Yi Shen, Hangxiang Fu and Lizhen Yu*

Abstract
Objective: To investigate the analgesic effect and rehabilitation quality of patients undergoing thoracoscopic wedge resection of the lung under erector spinae plane (ESP) block with dexmedetomidine combined with the same dose and different concentrations of ropivacaine.

Methods: Seventy patients undergoing thoracoscopic wedge resection were randomly divided into groups A (n = 35) and B (n = 35). To perform ESP block, the groups were administered dexmedetomidine (0.5 μg/kg) combined with 30 mL of 0.33% ropivacaine or 20 mL of 0.5% ropivacaine, respectively, half an hour before general anesthesia induction. We compared the onset time of anesthesia, the block level, and the duration of the block between the two groups. The number of compressions of the analgesic pump within 24 h and 48 h postoperatively and the time of the first compression were noted. The visual analog scale (VAS) scores of static and cough at 0.5 h, 6 h, 12 h, 24 h, and 48 h postoperatively were noted. Furthermore, the 40-item quality of recovery questionnaire (QoR-40) score was recorded at 24 h postoperatively. In addition, we noted the time taken to get out of the bed for the first time, the length of hospital stay, analgesia satisfaction, and the occurrence of related adverse reactions and complications within 48 h postoperatively.

Results: The range of ESP block was wider in Group A than in Group B (P < 0.05). Group B had a significantly shorter onset time (P < 0.05) and lower static and cough VAS scores at 6 h and 12 h postoperatively (P < 0.05); this was
Introduction
At present, video-assisted wedge resection of the lung is widely considered an effective method for the treatment of early lung cancer. It offers the advantages of small incision, small trauma, and rapid recovery. However, most patients still report moderate pain, which gets particularly aggravated while coughing activity and affects their postoperative recovery. Erector spinae plane (ESP) block is reportedly safe to use in thoracic surgery; however, the duration of postoperative analgesia with a single local anesthetic is limited. Numerous studies have shown that dexmedetomidine as an adjuvant can significantly prolong the effect of local anesthetics for nerve block, reduce postoperative pain, reduce the dosage of local anesthetics and opioids, and reduce adverse reactions [1–6]. However, few studies have reported on the optimal concentration and dose ratio of dexmedetomidine with the local anesthetic in ESP block [7, 8]. This study was aimed at investigating the effect of dexmedetomidine co-administered with two different concentrations of ropivacaine (amounting to the same dose) for postoperative analgesia in terms of the analgesic effect and rehabilitation quality of patients undergoing thoracoscopic wedge resection of the lung to provide a reference for the concentration and dose of local anesthetics in patients undergoing ESP block for clinical thoracic surgery. The main clinical indicators used in this study were the VAS score at each postoperative time point and the postoperative QoR-40 score. Other indicators included the block level, time of the first compression of the analgesic pump, number of compressions of the analgesic pump, time to get out of the bed for the first time, and length of hospital stay.

Materials and methods
General data
This study was approved by the ethics committee of the Longyan First Affiliated Hospital of Fujian Medical University [Approval Number: (2019) Ethical Review Scientific Research No.28], and all patients signed the informed consent form. In addition, this study has been registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2200058114; registration time: 03/30/2022). According to inclusion and exclusion criteria, we selected 70 patients who underwent elective thoracoscopic wedge resection between June 2020 and November 2021. The selection was not influenced by the sex of the patient but was limited to patients aged 30–75 years with a body mass index (BMI) of 18–25 kg/m² and the American Society of Anesthesiologists (ASA) grade of I–III. The exclusion criteria were as follows: patients with block site infection, coagulation dysfunction, history of allergic response to local anesthesia, long-term use of anti-inflammatory and analgesic drugs during the recent 3 months, and severe cardiopulmonary, liver, kidney dysfunction and declined to participate.

Grouping and treatment
In the preliminary experiments, we selected patients undergoing thoracoscopic wedge resection of the lung in whom dexmedetomidine was co-administered with three local anesthetic concentrations of 0.25, 0.33, and 0.5% ropivacaine to induce ESP block before anesthesia; there were five patients in each group. The VAS scores of the three groups at each time point postoperatively were compared. The results showed that the three concentrations were safe and effective, but 0.33% ropivacaine and 0.5% ropivacaine had relatively superior analgesic effect. Accordingly, the patients were randomly divided into two groups of 35 individuals. Group A received 0.5-μg/kg dexmedetomidine + 30 mL of 0.33% ropivacaine half an hour before general anesthesia induction; Group B received 0.5-μg/kg dexmedetomidine + 20 mL of 0.5% ropivacaine.

Anesthesia methods
Patients in both groups were treated with intravenous compound general anesthesia, wherein 0.02–0.03-mg/kg midazolam, 0.2-mg/kg etomidate, 0.2–0.4-μg/kg sufentanil, and 0.15-mg/kg atracurium were injected intravenously. Endotracheal intubation was performed after nitrogen removal and oxygen supply for 5 min. The parameters were set as follows: tidal volume, 8–10 mL/
kg; respiratory rate, 10–12 times/min; inspiration and expiration ratio, 1:2; and end-tidal CO₂ partial pressure, 35–45 mmHg. Furthermore, 5–10 μg of sufentanil was added before the operation. For anesthesia maintenance, intravenous infusion of propofol (50–80 μg·kg⁻¹·min⁻¹) and remifentanil (0.2–0.6 μg·kg⁻¹·min⁻¹) was started. Hemodynamic stability was adjusted accordingly, and end-tidal CO₂ partial pressure was maintained at 30–40 mmHg; 5 μg of sufentanil was added if necessary. The endotracheal tube was removed once the patient met the extubation indication. Patient-controlled intravenous analgesia was used postoperatively with 2 μg/kg sufentanil + 4 mg/kg flurbiprofen + 10 mg of tropisetron + normal saline diluted to 100 mL; load dose was 3 mL, background dose was 3 mL/h, and additional dose was 3 mL. The locking time was 20 min.

ESP block
Patients in both groups underwent ESP block half an hour before general anesthesia induction. While the patient was in the lateral position, the high-frequency linear ultrasonic probe (M7 Exp, Shenzhen Mairui Biomedical Electronics Co, Ltd.) was placed in the longitudinal sagittal direction at 3 cm outside the T5 spinous process. The trapezius muscle, rhomboid muscle, erector spinae muscle, and the tip of the T5 transverse process could be clearly visualized from the top to the bottom. Using the in-plane technique, local anesthetics were injected when the tip of the needle reached between the erector spinae muscle and the transverse process. Another anesthesiologist who was blinded to the grouping measured the block plane by acupuncture 30 min after performing the block.

Outcome measures
The onset time, plane, and duration of the block were recorded. The visual analog scale (VAS) score was used to evaluate the severity of pain. One day before the operation, the anesthesiologist explained the VAS scoring rules to the patients, with 0 representing no pain and 10 representing unbearable pain, and the patients selected a number from 0 to 10 based on their perception of pain. The patients were instructed to press the analgesic device when they perceived their conscious VAS score to be greater than 3 for patient-controlled analgesia. The VAS scores were recorded at rest and while coughing at 0.5 h, 6 h, 12 h, 24 h, and 48 h postoperatively. The number of times the analgesic pump was pressed and the postoperative time point at which the analgesic pump was pressed for the first time were noted at 24 h and 48 h postoperatively. The time taken to get out of the bed for the first time and the time of hospitalization were recorded. The patients were followed up 24 h postoperatively, and at the same time, the QoR-40 questionnaire was administered to score the quality of life. The analgesia satisfaction of patients with postoperative analgesia was recorded on a scale of 0–100 points at 48 h postoperatively. At the same time, the occurrence of adverse reactions or complications, such as respiratory depression, nausea and vomiting, hypotension, bradycardia, and local anesthetic toxicity within 48 h postoperatively were recorded.

Statistical methods
In our preliminary study, we have proved that 0.33% ropivacaine and 0.5% ropivacaine had relatively super analgesic effect than 0.25% ropivacaine. In the next preliminary experiments, 10 eligible patients with thoracoscopic wedge resection were randomly divided into group A (dexmedetomidine combined with 0.33% ropivacaine, n = 5) and group B (dexmedetomidine combined with 0.50% ropivacaine, n = 5). The static VAS score at 6 h postoperatively was selected for analysis. The mean static VAS scores at 6 h postoperatively were 1.95 ± 0.80 and 1.25 ± 0.75 in groups A and B, respectively. This score for group B was significantly lower than that for group A (P < 0.05). PASS (version 11.0.7, NCSS LLC) for Windows was used to calculate the sample size. The Student t test was used, and the group allocation ratio was equal. Then, we calculated that a sample of 24 patients would provide 90% power at a two-sided α level of 0.05. Finally, we recruited 35 patients in each group for a total of 70 patients while taking into consideration the possibility of dropouts and incomplete follow-ups (20%). Therefore, 70 patients were included in this study. SPSS 23.0 (IBM Inc., New York, NY) was the statistical software used for analysis. The measurement data are expressed as mean ± standard deviation (x̄ ± s). Notably repeated measures analysis of variance (ANOVA) was adopted for between-group comparisons, and multivariate ANOVA was adopted for between-group comparisons at each time point. The counting data were described using rate and ratio, and the chi-square (χ²) test was used for between-group comparisons. The difference was statistically significant (P < 0.05).

Results
There was no significant difference in age, sex, weight, BMI, operation time, and the ASA grade between the two groups (Table 1). All patients completed the trial. In Group A, the ESP block was performed in the T3–T7 spinal nerve innervation area in 19 cases and in the T2–T8 spinal nerve innervation area in 16 cases. In Group B, the ESP block was performed in the T3–T7 spinal nerve innervation area in 20 cases and in the T2–T8 spinal nerve innervation area in 15 cases. The onset time was shorter for Group B than for Group A (P < 0.05; Table 2). There was no significant difference in the ESP block
duration between the two groups (Table 2). Compared with Group A, the VAS scores of quiescence and cough at 6 h and 12 h postoperatively were significantly lower in Group B \( (P < 0.05; \text{Table } 3) \). The VAS scores of the two groups did not significantly differ at 0.5 h, 24 h, and 48 h postoperatively (Table 3). The number of times the analgesic pump was pressed as noted at 24 h and 48 h postoperatively was significantly lower in Group B \( (P < 0.05; \text{Table } 2) \), and the time before the analgesic pump was pressed for the first time was significantly longer in Group B \( (P < 0.05; \text{Table } 2) \).

Compared with Group A, the QoR-40 score was significantly higher \( (P < 0.05) \) and the time taken to get out of the bed for the first time was significantly shorter in Group B \( (P < 0.05) \); there was no significant between-group difference in the length of hospital stay (Table 4). In addition, ESP block-related adverse reactions and complications did not significantly differ between the two groups (Table 5). In both groups, one patient experienced nausea and vomiting. One patient in Group A had bradycardia and one patient in Group B had hypotension. There were no adverse reactions or complications, such as respiratory depression, infection, nerve injury, and local anesthetic toxicity.

### Discussion

This study adopts a randomized, controlled, and double-blinded method. The results revealed that ultrasound-guided dexmedetomidine combined with different concentrations of ropivacaine for ESP block showed a good analgesic effect in patients undergoing thoracoscopic wedge resection. In terms of the overall postoperative analgesic effect and the rehabilitation

---

**Table 1** Comparison of general data between the two groups \( (n = 35) \)

| Groups | Group A | Group B | \( p \) |
|--------|---------|---------|------|
| Age    | 54.17 ± 5.89 | 55.51 ± 5.91 | 0.896 |
| Gender (male / female) | 21/14 | 23/12 | 0.621 |
| Weight (kg) | 63.60 ± 7.63 | 61.54 ± 8.20 | 0.281 |
| BMI (kg/m²) | 23.49 ± 1.68 | 23.29 ± 1.62 | 0.613 |
| ASA (I/II/III) | 3/28/4 | 4/27/4 | 0.923 |

*Comparison of general data between the two groups*

**Table 2** The level block of erector spinae muscle and the analgesic pump pressure in the two groups \( (n = 35) \)

| Groups | Onset time (min) | Duration (h) | No. of times the analgesic pump was pressed 24 h 48 h | First press time (h) |
|--------|-----------------|--------------|--------------------------------------------------|--------------------|
| Group A | 14.94 ± 1.28    | 15.43 ± 2.44 | 3.83 ± 0.79 5.14 ± 0.97                         | 5.17 ± 1.12        |
| Group B | 12.26 ± 1.87 \( ^a \) | 16.34 ± 2.42 | 1.46 ± 0.92 4.06 ± 0.73 \( ^a \)               | 5.86 ± 1.00 \( ^a \) |
| \( p \) | < 0.001         | 0.121        | \(< 0.001 \) \(< 0.001 \)                       | 0.009              |

*Notes: Compared with group A, \( ^a p < 0.05 \)*

**Table 3** Comparison of resting and cough VAS scores and QoR-40 score between the two groups \( (\text{score, } \overline{x} ± s, n = 35) \)

| Evaluation status | Group | 0.5 h       | 6 h         | 12 h        | 24 h       | 48 h        |
|-------------------|-------|-------------|-------------|-------------|------------|-------------|
| Static VAS        | Group A | 0.97 ± 0.62 | 1.97 ± 0.79 | 2.63 ± 0.60 | 2.51 ± 0.51 | 2.37 ± 0.55 |
| Group B           | 0.94 ± 0.60 | 1.00 ± 0.64 \( ^a \) | 1.86 ± 0.65 \( ^a \) | 2.49 ± 0.66 \( ^a \) | 2.26 ± 0.66 \( ^a \) |
| \( p \)           | 0.056 | \(< 0.001 \) | \(< 0.001 \) | \(< 0.001 \) | 0.196 | 0.110       |
| Cough VAS         | Group A | 3.71 ± 0.67 | 3.86 ± 0.69 | 4.17 ± 0.75 | 4.54 ± 0.56 | 3.97 ± 0.71 |
| Group B           | 3.43 ± 0.56 | 3.29 ± 0.57 \( ^a \) | 3.34 ± 0.59 \( ^a \) | 4.29 ± 0.75 | 3.66 ± 0.91 |
| \( p \)           | 0.056 | \(< 0.001 \) | \(< 0.001 \) | \(< 0.001 \) | 0.109 | 0.110       |

*VAS Visual analog score; Compared with group A, \( ^a p < 0.05 \)*

**Table 4** Comparison of rehabilitation quality between the two groups \( (n = 35) \)

| Group | Group A | Group B | \( p \) |
|-------|---------|---------|------|
| Time taken to get out of the bed for the first time (days) | 1.31 ± 0.13 | 1.03 ± 0.13 \( ^a \) | < 0.001 |
| Length of postoperative hospital stay (days) | 3.04 ± 0.22 | 2.97 ± 0.20 | 0.169 |
| QoR-40 scores | 170.91 ± 3.90 | 177.63 ± 4.88 \( ^a \) | < 0.001 |
| Analgesia satisfaction | 85.63 ± 2.59 | 90.00 ± 3.15 \( ^a \) | < 0.001 |

*Notes: compared with group A, \( ^a p < 0.05 \)*

**Comparison of rehabilitation quality between the two groups**

---

**Table 5** Comparison of rehabilitation quality between the two groups

| Group | Group A | Group B | \( p \) |
|-------|---------|---------|------|
| Time taken to get out of the bed for the first time (days) | 1.31 ± 0.13 | 1.03 ± 0.13 \( ^a \) | < 0.001 |
| Length of postoperative hospital stay (days) | 3.04 ± 0.22 | 2.97 ± 0.20 | 0.169 |
| QoR-40 scores | 170.91 ± 3.90 | 177.63 ± 4.88 \( ^a \) | < 0.001 |
| Analgesia satisfaction | 85.63 ± 2.59 | 90.00 ± 3.15 \( ^a \) | < 0.001 |

*Notes: compared with group A, \( ^a p < 0.05 \)*

**Comparison of rehabilitation quality between the two groups**
The analgesic mechanism of dexmedetomidine mainly involves constricting the surrounding blood vessels to delay the absorption of local anesthetics [16]. In addition, dexmedetomidine directly affects the activity of peripheral neurons by acting on the adrenergic receptor (peripheral apparatus) to enhance the time effect of local anesthesia [17, 18]. Finally, dexmedetomidine maintains the hyperpolarization potential of the cell membrane by inhibiting hyperpolarization-activated cation current to inhibit the return of membrane potential to the resting potential level [19]. Gao et al. [3] showed that dexmedetomidine (1 μg/kg) when added to 0.5% ropivacaine can prolong the ESP block time of patients undergoing thoracoscopy by approximately 120% (approximately 18h), which is significantly longer than the ESP block times in the group using 0.5% ropivacaine alone and the group with dexamethasone (10 mg) added to 0.5% ropivacaine. In the present study, the concentration of dexmedetomidine was 0.5 μg/kg in Group B, and the ESP block duration was slightly lower than that reported by Gao et al [3] Our preliminary experiments findings and several previous studies [3, 20–22] have shown that dexmedetomidine (1 μg/kg) when added to local anesthetics can significantly prolong the nerve block time, stabilize the intraoperative hemodynamics, significantly reduce the postoperative VAS score, and significantly limit the administration of postoperative analgesic drugs. Vorobeichik et al. found that 50–60-μg dexmedetomidine dose can maximize the duration of sensory block and minimize hemodynamic side effects. No patients had any neurological sequelae, and the evidence of sensory block was of high quality [23]. Abdulatif et al. used dexmedetomidine as an adjuvant at 50 μg and 75 μg doses. The 50-μg dose was associated with lesser time before postoperative morphine was needed, prolonged time to achieve sensory block, and the lesser time before the first rescue analgesia was administered; however, increasing the dose of dexmedetomidine to 75 μg was associated with an increased risk of hypotension [24]. Therefore, when dexmedetomidine at high doses is used as an adjuvant for nerve block, we should be vigilant against the occurrence of adverse reactions, such as hypotension and bradycardia. Therefore, 0.5-μg/kg dexmedetomidine was used in this study.

Ultrasound-guided ESP block is a new fascial space block. It offers the advantages of simple operation, safety, high success rate of block puncture, and few operation-related complications [25]. Fredrickson et al. [26] found that concentration and volume (and thus mass) of local anesthetics were clearly associated with prolonged analgesia. In this study, it was also observed that the effect of 0.5% ropivacaine was significantly faster and lasted

| Comparison of adverse reactions and complications between the two groups (n = 35) |
|-------------------------------|----------------|----------------|----------------|
|                               | Group A | Group B | P       |
| Nausea and vomiting         | 1       | 1       | >0.999  |
| Respiratory depression      | 0       | 0       | >0.999  |
| Hypotension                 | 0       | 1       | 0.314   |
| Bradycardia                 | 1       | 0       | 0.314   |
| Infection                   | 0       | 0       | >0.999  |
| Nerve injury                | 0       | 0       | >0.999  |
| Local anesthetic toxicity   | 0       | 0       | >0.999  |

quality of patients undergoing thoracoscopic wedge resection of the lung, dexmedetomidine is better combined with 0.5% ropivacaine than with 0.33% ropivacaine for ESP block.

After leaving the intervertebral foramen, each thoracic spinal nerve bifurcates into a dorsal branch and a ventral branch. Among these, the dorsal branch runs behind the transverse costal process and innervates the erector spinae muscle, the rhomboid muscle, and the trapezius muscle upwards. The ventral branch becomes the intercostal nerve. ESP block can completely cover the walking range of the dorsal and ventral branches of the thoracic spinal nerve. Therefore, its block range is wider than that of the intercostal nerve. Notably, 0.2% levobupivacaine and 0.2–0.5% ropivacaine are the commonly used drug concentrations for peripheral nerve block in clinical anesthesia. Relevant studies have used these concentrations of these local anesthetic solutions to observe the analgesic effect after ESP block [9–13]. Compared with levobupivacaine, ropivacaine is characterized by fewer cardiotoxic effects and a probably greater margin of safety [14]. In addition, levobupivacaine is characterized by an outstanding myotoxic potential [14]. The preliminary experiments showed that ESP block with 0.33 and 0.5% ropivacaine had a better analgesic effect than that with 0.25% ropivacaine. Therefore, this study used ropivacaine at 0.33 and 0.5% concentrations, which are commonly used clinically, for ultrasound-guided ESP block and observed the analgesic effect of concentrations after thoracoscopic wedge resection when the overall dose administered was the same. In this study, the block plane was measured 30 min after ESP block because the average blood concentration of ropivacaine peaked 30 min after administration [15].

Dexmedetomidine is a new type of high-selectivity α2 adrenergic agonist and has sedative, analgesic, antianxiety, and antisymptomatic properties, which are beneficial for the postoperative recovery of patients.
significantly longer than that of 0.33% ropivacaine, which is consistent with existing literature [27]. However, Hillenn Cruz Eng et al. report that the mass of local anesthetics rather than their concentration or volume is the most important determinant of peripheral nerve block onset and duration [28]. Deng et al. compared three concentrations (0.2, 0.3, and 0.4%) of ropivacaine to improve thoracic nerve block in radical mastectomy. The results showed that the postoperative pain scores associated with 0.3 and 0.4% concentrations were significantly higher than those associated with 0.2% concentration \( P < 0.05 \), and there was no significant difference between 0.3 and 0.4% concentrations [29]. In the present study, Group B patients were found to have pressed the analgesic pump significantly fewer times than Group A patients at 24 h and 48 h postoperatively. Furthermore, the time before the patients felt the need to press the analgesic pump for the first time was longer in Group B than in Group A. In addition, the VAS score of Group B patients at 6 h and 12 h postoperatively was lower than that of Group A, indicating that the analgesic effect of 0.5% ropivacaine was better than that of 0.33% ropivacaine for the same overall dose administered, particularly within 12 h from the operation. Appropriate postoperative analgesia is associated with greater comfort, reduced dosages of postoperative analgesics, early resumption of activities, reduced risk of pulmonary complications, and shorter the length of hospital stay [3]. There was no significant difference between the two groups at 24 h and 48 h postoperatively, which may be attributed to the limited duration of a single ESP block. Continuous ESP block can be explored for its benefits and limitations in future research. In this study, there was no significant difference in postoperative ESP-related adverse reactions and complications between the two groups.

QoR-40 is an effective patient-centered multidimensional quality assessment tool [30]. Myles et al. reported that an increase of 6.3 or more in the overall QoR-40 score represents a clinically relevant improvement in the quality of postoperative recovery [31]. In this study, the QoR-40 score of patients in Group B was 6.7 points higher than that of patients in Group A \( P < 0.05 \). In Group B, the time taken to get out of the bed for the first time was reduced, and the satisfaction scores of patients with the analgesic effect were higher. These findings were considered to be attributed to the lower VAS score and better analgesia in Group B. In addition, in Group B, the number of times the analgesic pump was pressed postoperatively was fewer and the use of opioids was lesser, which can reduce the adverse effects caused by opioids, can improve the comfort and satisfaction of patients with the analgesic effect, and is conducive to the postoperative rehabilitation of patients, which is consistent with the existing literature [32–34]. However, the two groups did not significantly differ in terms of the length of postoperative hospital stay. This finding could be influenced by the small sample size, and this aspect needs to be further studied in future research.

The inadequacies of this study are limited by the research conditions. In this study, acupuncture was used to determine the block plane, which was relatively subjective; however, the time from the completion of ESP to patients’ postoperative pain is regarded as the duration of ESP block analgesia. In addition, this study was a single-center study with a small sample size, and its conclusion needs to be further confirmed by expanding the sample size. Further large studies are needed to assess the safety and efficacy of the ESP block.

**Conclusions**

Dexmedetomidine combined with 0.5% ropivacaine provided effective pain control postoperatively and reduced the need for rescue analgesia. It also more significantly improved the postoperative rehabilitation quality for patients undergoing thoracoscopic wedge resection of the lung.

**Abbreviations**

- ESP: Erector spinae plane
- VAS: Visual analog scale
- QoR-40: The 40-item quality of recovery questionnaire
- BMI: Body mass index
- ASA: American Society of Anesthesiologists
- ANOVA: Repeated measures analysis of variance

**Authors’ contributions**

Yi Shen carried out the literature research and prepared the figure and tables. Hangxiang Fu collected the clinical details and data and analyzed and interpreted the data. Chunfang Jian made a major contribution to complete the manuscript. Lizhen Yu provided administrative support, critically reviewed the intellectual content of the article, and wrote the manuscript. All authors have read and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable requests. The datasets generated during and/or analyses during the current study are also available in the Research Manager.

**Declarations**

**Ethics approval and consent to participate**

The experimental protocol was established according to the ethical guidelines of the Declaration of Helsinki (2008) and was approved by the Human Ethics Committee of the Longyan First Affiliated Hospital to Fujian Medical University [Approval Number: (2019) Ethical Review Scientific Research No.28]. In addition, this study has been registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2200058114 (registration time: 03/30/2022). Written informed consent was obtained from all participants or their guardians.

**Consent for publication**

Written informed consent for the publication of clinical details was obtained.
References
1. Shi L, Guo C, Xie Y, Liu Y, Wu F. Dexmedetomidine attenuates lung injury in obstructive jaundice rats through PI3K/Akt/HIF-1α signaling pathway. Arch Med Res. 2019;50(5):233–40.
2. Yuan M, Meng XW, Ma J, et al. Dexmedetomidine protects HK-2 cardiomyocytes against oxygen-glucose deprivation/reoxygenation-induced intracellular calcium overload and apoptosis through regulating PI3K/R2/6/PyK2 signaling. Drug Des Devel Ther. 2019;13:3137–49.
3. Gao Z, Xiao Y, Wang Q, Li Y. Comparison of dexmedetomidine and dexamethasone as adjuvant for ropivacaine in ultrasound-guided erector spinae plane block for ventral-thoracic surgery: a randomized, double-blind, placebo-controlled trial. Acta Anaesthesiol Scand. 2019;63(2):166–72.
4. Wang X, Ran G, Chen X, et al. The effect of ultrasound-guided erector spinae plane block combined with dexmedetomidine on postoperative analgesia in patients undergoing modified radical mastectomy: a randomized controlled trial. Pain Ther. 2021;10(1):475–84.
5. Coviello A, Esposito D, Galletta R, Maresca A, Servillo G. Opioid-free anesthesia-dexmedetomidine as adjuvant in erector spinae plane block: a case series. J Med Case Rep. 2021;15(1):276.
6. Schwartz R, Urits I, Viswanath O, Kaye AD, Eskander J. Use of erector spinae plane block for perioperative pain control in a patient undergoing spinal surgery. Cureus. 2020;12(8):e9646.
7. Gao X, Zhao T, Gu C, Ren C, Liu G, Du K. The efficacy and safety of ultrasound-guided, bi-level, erector Spinae plane block with different doses of Dexmedetomidine for patients undergoing video-assisted thoracic surgery: a randomized controlled trial. Front Med (Lausanne). 2021;8:577885.
8. Altparmak B, Korkmaz Taker M, Uysal AI, Gumus DS. Comparison of the efficacy of erector spinae plane block performed with different concentrations of ropivacaine on postoperative analgesia after mastectomy surgery: randomized, prospective, double blind clinical trial. BMC Anesthesiol. 2019;19(1):31.
9. Vidéal E, Giménez H, Forero M, Sandoval O. Ultrasound-guided bilateral erector spinae plane block for postoperative pain control: a cadaver study to determine its mechanism of action. Rev Esp Anestesiol Reanim (Engl Ed). 2018;65(9):514–9.
10. Gürkan Y, Aksoy C, Kuş A, Yörüköğlu UH, Kılıç CT. Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: a randomized controlled study. J Clin Anesth. 2018;49:50–5.
11. Chen N, Qiao Q, Chen R, Xu Q, Zhang Y, Tian Y. The effect of ultrasound-guided interscostal nerve block, single-injection erector spinae plane block and multiple-injection paravertebral block on postoperative analgesia in thoracoscopic surgery: a randomized, double-blind trial. J Clin Anesth. 2020;59:106–11.
12. Gürkan Y, Aksoy C, Kuş A, Yörüköğlu UH. Ector spinae plane block and thoracic paravertebral block for breast surgery compared to IV-morphine: a randomized controlled trial. J Clin Anesth. 2020;59:884–8.
13. Verma R, Srivastava D, Saxena R, et al. Ultrasound-guided bilateral Ector Spinea plane block for postoperative analgesia in laparoscopic cholecystectomy: a randomized controlled trial. Anesth Essays Res. 2020;14(4):226–32.
14. Zink W, Graf BM. The toxicity of local anesthetics: the place of ropivacaine and levobupivacaine. Curr Opin Anaesthesiol. 2008;21(5):645–50.
15. Griffiths JD, Barron FA, Grant S, Bjorksten AR, Hebbard P, Royse CF. Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block. Br J Anaesth. 2010;105(6):853–6.
16. Zhang X, Bai X. New therapeutic uses for an alpha2 adrenergic receptor agonist—dexmedetomidine in pain management. Neurosci Lett. 2014;561:7–12.
17. Chiu KM, Lin TY, Lu CW, Wang SJ. Inhibitory effect of glutamate release from rat cerebrocortical nerve terminals by α2 adrenoceptor agonist dexmedetomidine. Eur J Pharmacol. 2011;670(1):137–47.
18. Kimura M, Saito S, Obata H. Dexmedetomidine decreases hyperalgesia in neuropathic pain by increasing acetylycholine in the spinal cord. Neurosci Lett. 2012;529(1):70–4.
19. Brummett CM, Hong EK, Janda AM, Amoedo FS, Lydic R. Perineural dexmedetomidine added to ropivacaine for sciatic nerve block in rats prolongs the duration of analgesia by blocking the hyperpolarization-activated cation current. Anesthesiology. 2011;115(4):836–43.
20. Kumari P, Singh RB, Saurabh K, Pal S, Ram GK, Anand RK. To compare the efficacy of postoperative analgesia between donezide and Dexmedeto-midine as adjuvants with 0.5% Ropivacaine by ultrasound-guided supra-clavicular brachial plexus block for upper limb surgery: a prospective, double-blind, randomized study. Anesth Essays Res. 2020;14(4):644–52.
21. Akso R, Bicer C. Addition of dexmedetomidine to bupivacaine in supra-clavicular brachial plexus block. Clin Invest Med. 2017;40(3):E111–6.
22. Manzoor S, Taneja R, Sood N, Puri A, Kadlayaprag P. Comparative study to assess the quality of analgesia of bupivacaine and bupivacaine with dexmedetomidine in ultrasound-guided pectoral nerve block type I and II in breast surgeries. J Anaesthesiol Clin Pharmacol. 2018;34(2):227–31.
23. Vorbeischl B, Brull R, Abdallah FW. Evidence basis for using perineural dexmedetomidine to enhance the quality of brachial plexus nerve blocks: a systematic review and meta-analysis of randomized controlled trials. Br J Anaesth. 2017;118(2):167–81.
24. Abdullatif M, Fawzy M, Nassar H, Hasanin A, Ollaek M, Mohamed H. The effects of perineural dexmedetomidine on the pharmacodynamic profile of femoral nerve block: a close-finding randomised, controlled, double-blind study. Anaesth. 2016;71(10):1177–85.
25. De Cassai A, Bonvivici D, Coreale C, Sandel L, Tulgar S, Tonetti T. Ercotor spinea plane block: a systematic qualitative review. Minerva Anestesiol. 2019;85(3):308–19.
26. Fredrickson MJ, Abeyshekera A, White R. Randomized study of the effect of local anesthetic volume and concentration on the duration of peripheral nerve blockade. Reg Anesth Pain Med. 2012;37(5):495–501.
27. El-Sharrawy E, Yagela JA. Anesthetic efficacy of different ropivacaine concentrations for inferior alveolar nerve block. Anesth Prog. 2006;53(1):13–7.
28. Eng HC, Ghosh SM, Chin KJ. Practical use of local anesthetics in regional anesthesia. Curr Opin Anaesthesiol. 2014;27(4):382–7.
29. Deng W, Fu D, He L. Evaluation of pectoral nerve block in modified radical mastectomy: comparison of three concentrations of Ropivacaine. Clin Interv Aging. 2020;15:937–44.
30. Myles PS, Myres DB, Galagher W, Chetwynn D, Donaldson N, Dennis A. Minimal clinically important difference for three quality of recovery scales. Anesthesiology. 2016;125(1):39–45.
31. Macaire P, Ho N, Nguyen T, et al. Ultrasound-guided continuous thoracic erector Spinae plane block within an enhanced recovery program is associated with decreased opioid consumption and improved patient postoperative rehabilitation after open cardiacl surgery—a patient-matched, controlled before-and-after study. J Cardiothorac Vasc Anesth. 2019;33(6):1659–67.
32. Finnerty DT, McNamara J, Hartigan SD, Griffin M, Buggy DJ. Comparing erector Spinae plane block with serratus anterior plane block for minimally invasive thoracic surgery: a randomised clinical trial. Br J Anaesth. 2020;125(5):802–10.
33. Fu J, Zhang G, Qiu Y. Ector spinae plane block for postoperative pain and recovery in hepatectomy: a randomized controlled trial. Medicine (Baltimore). 2020;99(41):e22251.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.